Annovis Bio Inc Market Cap ($35.94 Million)
Market Cap & Net Worth: Annovis Bio Inc (ANVS)
Annovis Bio Inc market cap. Annovis Bio Inc (NYSE:ANVS) has a market capitalization of $35.94 Million ($35.94 Million) as of November 8, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #22857 globally and #5019 in its home market, demonstrating a -17.17% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Annovis Bio Inc's stock price $0.84 by its total outstanding shares 42541868 (42.54 Million). Also see cash efficiency ratio of Annovis Bio Inc for how efficiently the company converts equity into cash flow.
Annovis Bio Inc Market Cap History (2020–2026)
Annovis Bio Inc market cap history from 2020 to 2026. Data shows change from $320.77 Million to $35.94 Million (-30.13% CAGR). Check Annovis Bio Inc stock price for real-time trading data and today's change.
Annovis Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Annovis Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ANVS shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ANVS by Market Capitalization
Companies near Annovis Bio Inc in the global market cap rankings as of November 8, 2026. Also see how large is Annovis Bio Inc's balance sheet for a full breakdown of the balance sheet.
Key companies related to Annovis Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Annovis Bio Inc (2020–2026)
Market capitalization of Annovis Bio Inc from 2020 to today. Between 2020 and today, Annovis Bio Inc's market cap moved from $320.77 Million to $ 35.94 Million, with a yearly change of -30.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $35.94 Million | -75.58% |
| 2025 | $147.19 Million | -31.21% |
| 2024 | $213.99 Million | -73.10% |
| 2023 | $795.53 Million | +39.24% |
| 2022 | $571.34 Million | -23.61% |
| 2021 | $747.89 Million | +133.16% |
| 2020 | $320.77 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Annovis Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $35.94 Million USD |
| MoneyControl | $35.94 Million USD |
| MarketWatch | $35.94 Million USD |
| marketcap.company | $35.94 Million USD |
| Reuters | $35.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury… Read more